Updated evidence of the Naoshuantong capsule against ischemic stroke: a systematic review and meta-analysis of randomized controlled trials
Aktuelle Evidenz zur Naoshuantong-Kapsel bei ischämischem Schlaganfall: systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien
Frontiers in Pharmacology · 26.09.2024 · 15
DOI: 10.3389/fphar.2024.1434764 ↗Auf einen Blick
27 RCTs mit 3.139 Patient:innen: Die Naoshuantong-Kapsel verbesserte neurologische und funktionelle Ergebnisse bei ischämischem Schlaganfall und senkte die Rezidivrate.
Fragestellung
Wirkt die Naoshuantong-Kapsel bei Patient:innen mit ischämischem Schlaganfall wirksam und sicher?
Methode
Systematische Übersicht und Metaanalyse von RCTs; Suche in 8 Datenbanken; Bewertung mit Cochrane risk assessment scale; Analyse mit RevMan 5.3 und Stata 14.0.
Ergebnisse
27 RCTs mit 3.139 Patient:innen. NIHSS akut: MD −2,53 (95 %-KI −2,91 bis −2,15); NIHSS nicht akut: MD −3,70 (95 %-KI −5,82 bis −1,58); mRS: MD −0,68 (95 %-KI −1,09 bis −0,26); Rezidiv: RR 0,43 (95 %-KI 0,27 bis 0,70); SS-QOL akut: MD 23,88 (95 %-KI 16,63 bis 31,13).
Einschränkungen
Die Evidenzsicherheit wurde als moderat bis sehr niedrig eingestuft; schlechte Studienqualität und Heterogenität der eingeschlossenen Studien.
Schlussfolgerung der Autor:innen
Die Naoshuantong-Kapsel erscheint als potenziell wirksame und sichere Behandlungsoption bei ischämischem Schlaganfall; größere standardisierte RCTs sind nötig.
Kernaussagen
- Verbesserung der neurologischen Funktion in der akuten und nicht akuten Phase
- Niedrigere mRS-Werte und geringere Rezidivrate
- Keine deutlichen Unterschiede bei unerwünschten Ereignissen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 26.09.2024. Verfasst von Cuilin Que und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Stroke is a serious health issue that can result in death or disability, leading to a significant economic strain on society and families. A growing number of studies have shown that the Naoshuantong capsule (NSTC) is beneficial as a treatment for ischemic stroke (IS) in recent years. Our study aims to provide an update on the safety and efficacy of the NSTC in IS patients.
Methods
We thoroughly searched eight databases to identify suitable randomized controlled trials (RCTs) assessing the effectiveness of the NSTC in the treatment of IS. The National Institute of Health Stroke Scale (NIHSS) for an acute period and modified Rankin Scale (mRS) at 3 months for a non-acute period were considered the primary outcome, and secondary outcomes included the NIHSS for a non-acute period, mRS, Barthel Index (BI), modified Barthel Index (MBI), Stroke-specific Quality of life (SS-QOL), and the recurrence rate of cerebrovascular events. Subsequently, its quality was assessed using the Cochrane risk assessment scale. Statistical analysis was conducted using RevMan 5.3 and Stata 14.0.
Results
A total of 27 RCTs were included, which involved 3,139 patients. The results showed that the NSTC improved neurological function not only in the acute period (MD = −2.53; 95% CI: −2.91, −2.15; p < 0.00001) but also in the non-acute period (MD = −3.70; 95% CI: −5.82, −1.58; p = 0.0006) and improved the long-term functional outcomes with lower mRS scores (MD = −0.68; 95% CI: −1.09, −0.26; p = 0.001). At the same time, the NSTC decreased the risk of cerebrovascular disease recurrence (RR = 0.43; 95% CI: 0.27, 0.70; p = 0.0006) and increased the quality of life in the acute period (MD = 23.88; 95% CI: 16.63, 31.13; p < 0.00001). Significant disparities in the incidence of adverse events between the NSTC and control groups were not observed. The certainty of evidence was estimated as moderate to very low.
Conclusion
The NSTC emerges as a potentially efficacious and safe treatment option for IS. NSTC could improve neurological function in different period of IS, and it has certain clinical value in secondary prevention. As a result of the poor quality and heterogeneity of the included trials, larger and standardized RCTs are needed to validate NSTC in IS treatment. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=482981 , identifier CRD42023482981.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
- Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing, China.
- Beijing University of Chinese Medicine, Beijing, China.
- Chinese Medicine Key Research Room of Brain Disorders Syndrome and Treatment of the National Administration of Traditional Chinese Medicine, Beijing, China.
Zitieren
APA
Que, C., Wei, Y., Yin, G., Zhou, C., Liu, Z., Lai, X., Qin, M., Xiong, X., Zheng, X., Dong, X., & Gao, Y. (2024). Updated evidence of the Naoshuantong capsule against ischemic stroke: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1434764
Vancouver
Que C, Wei Y, Yin G, Zhou C, Liu Z, Lai X, et al. Updated evidence of the Naoshuantong capsule against ischemic stroke: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1434764
BibTeX
@article{Que2024,
author = {Que, Cuilin and Wei, Yupeng and Yin, Guanxiang and Zhou, Congren and Liu, Zhenhong and Lai, Xinxing and Qin, Mingzhen and Xiong, Xuejiao and Zheng, Xiangyi and Dong, Xinglu and Gao, Ying},
title = {Updated evidence of the Naoshuantong capsule against ischemic stroke: a systematic review and meta-analysis of randomized controlled trials},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1434764}
}
EUVIMED